On this page
The research desk’s view
A current MOTS-c injection listing, with important package details still requiring a written quote.
The listing, in detail
- Published card
- $265 per month
- Named format
- MOTS-C subcutaneous injection
- Follow-up described
- Provider check-ins and messaging
- Purchase condition
- Clinical screening and individual prescription decision
What the listing establishes
- MOTS-c route and monthly card are visible
- Clinical follow-up features are described
What it leaves unanswered
- Exact supply is not established by the monthly label
- No consumer outcome can be inferred from the menu
What the product card actually establishes
YourEra lists a MOTS-C injection at $265 per month. That gives the comparison a real product and payment label rather than a general promise of longevity care. The card should nevertheless be treated as the beginning of the inquiry. It is not a complete prescription, and the public monthly figure does not establish a standard quantity that can be matched to every other provider’s offer. The Amble MOTS-c review records an unusually explicit human-safety limitation on the product page. Compare how that uncertainty is explained as well as the commercial package.
Put the amount and the period together
Ask for the intended active amount, concentration, supply period and total payable before making a price comparison. The distinction matters even when two companies both use the word monthly. An interval between orders can reflect a clinical plan, a payment arrangement or both. The comparison worksheet should preserve those differences instead of reducing an incomplete quote to a deceptively simple per-day number.
Make the clinical conversation about the concern
A reader searching for metabolic health or energy support should explain the actual problem and existing care, rather than asking only whether the product can be purchased. Ask the clinician what alternatives should be considered and which evidence informs the proposed use. The consultation questions provide a way to make that conversation specific. They are not an eligibility quiz and do not supply a treatment schedule.
Check what happens after the first order
The card mentions check-ins and care messaging. Ask who handles new symptoms, how clinical changes are documented and how the pharmacy receives revised instructions. YourEra’s refund policy uses dispatch as a cutoff, so unresolved questions should be raised before an order is sent. Obtain confirmation of what a pause affects. Financial processing should follow a clinical decision about continuing care, rather than make that decision by default.
Metabolic language is not a measured benefit
The evidence guide explains the difference between a mitochondrial mechanism and evidence that administering a product changes a meaningful outcome in people. A provider’s product card does not bridge that gap. Ask whether the cited work concerns the same preparation and the same proposed goal. This review does not predict improved exercise capacity, weight loss or longevity, and it does not measure the quality of the clinician who may assess an individual reader.
A quote can make this comparison useful
HealthRX’s MOTS-c review describes a page with separate plan lengths and explicit monthly recurrence, while Amble’s review addresses a single-month bundle. Those comparisons show the kinds of payment and supply details worth obtaining from YourEra. The listing is relevant to a MOTS-c search, but any recommendation would need more than a catalog match. We have not completed intake, ordered medication or independently audited a dispensing pharmacy.
Read the source
Research findings and provider statements are different evidence.
- YourEra MOTS-C product cardCompany website
- YourEra dispatch and refund termsCompany website